Antibody-drug conjugates (ADCs) use biologics' targeting capabilities together with cytotoxic small molecule drugs, yet full-size antibody ADCs approved by the FDA face limitations in penetrating tumor tissue and achieving maximum therapeutic outcomes because of their complex structure. Creative Biolabs provides single domain antibody discovery and sdAb-based antibody-drug conjugate (ADC) development services, including end-to-end solutions for generating quality sdAb-based ADCs with comprehensive technical support.
Developing High-Quality SdAb-based ADC at Creative Biolabs
Creative Biolabs delivers complete solutions from single domain antibody discovery to sdAb-based antibody-drug conjugate development while manufacturing high-quality sdAb-based ADCs. The precision targeting of biologics paired with cytotoxic drugs forms ADCs, but full-sized antibodies struggle with effective tumor penetration due to their intricate structural complexity. Creative Biolabs utilizes 15 kDa sdAbs, which serve as the smallest functional antibody analogs possessing full antigen-binding domains. The compact structure of sdAbs permits them to recognize epitopes within dense and hidden targets while enabling tissue penetration through their molecular design.
Researchers can perform effective screening and execute precise site-specific modifications using their single-domain structure. Developing next-generation ADCs requires sdAb-based ADCs because they offer promising therapeutic potential. Our experienced team provides an effective comprehensive solution that features multiple sdAb-based conjugates with radioactive tracers, nanomaterials, gene products, along with immunomodulatory and cytotoxic reagents. The latest sdAb-based ADCs exhibit superior target accuracy combined with enhanced antitumor performance and minimal systemic toxicity, which leads to better targeted delivery.
Typical Pathway for SdAb-based ADC Development
Phase I Discovery
Target IdentificationMultiple target identification processes can be provided upon your request.
Typical Features of One-Stop for SdAb-based ADC Development
State-of-the-art technical platform for addressing challenging targets.
Holistic approaches to develop optimal solutions for sdAb-based ADCs.
Seasoned professional team possessing extensive expertise.
Entirely customizable proposal to fulfill specific requirements.
Fast turnaround time.
Dependable laboratory report with prompt updates.
Affordable price with the best quality.
Creative Biolabs is committed to supporting sdAb-based ADC development projects with exceptional quality and efficiency. Leveraging our robust platform and experienced scientists, we are confident in providing tailored, comprehensive
solutions to meet your specific needs. For further information, please do not hesitate to contact us.
Case Study
In this case study, TNFα protein was used as an antigen and a screening target. After the camelid immunization, library construction, and screening, 8 unique VHH sequences have been identified.
Figure 1. 3rd titration results.
After fourth animal injections, the test bleed was collected to monitor the immune response. The results showed that good immune response was obtained.
Figure 2. Process monitoring of library screening stage.
For this case study, a solid-phase screening strategy was used that the targets were immobilized on the plate surface. After three rounds of biopanning, good enrichment was observed. It showed that specific binders have been selected for the targets.
Figure 3. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
After the whole biopanning, 45 clones were randomly picked for the monoclonal phage ELISA. And 26 positive clones were observed for DNA sequencing. Finally, 8 unique clones were obtained.
Figure 1. 3rd titration results.
Figure 2. Process monitoring of library screening stage.
Figure 3. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
